Association Briefs

Dropouts Alarm Chemical Society Is the American Chemical Society (ACS) facing a membership crisis? Virtually stagnant growth in the ACS has prompted the group to forgo an increase in its $82 annual dues and to reexamine how it is perceived by its members. According to Attila E. Pavlath, chairman of the ACS membership committee, the 137,000-member organization gained only a net total of 14 new members last year. The preliminary findings of his study on the drop in renewals shows that the group

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Is the American Chemical Society (ACS) facing a membership crisis? Virtually stagnant growth in the ACS has prompted the group to forgo an increase in its $82 annual dues and to reexamine how it is perceived by its members. According to Attila E. Pavlath, chairman of the ACS membership committee, the 137,000-member organization gained only a net total of 14 new members last year. The preliminary findings of his study on the drop in renewals shows that the group is more likely to keep Ph.D.’s than those without advanced degrees. In addition, members seem to be jumping ship to join more specialized professional organizations, like those catering to electrochemical engineers. At the ACS April meeting in Dallas, a warning from Pavlath. that some members were balking at the cost of remaining in the society persuaded the leadership not to raise dues for the first time since 1974. The society is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies